Sequence Information

    • DRAMP ID

    • DRAMP29326

    • Name

    • LTX-315(Oncopore, Ruxotemitide)

    • Sequence

    • KKWWKKWXK

    • Description

    • Ruxotemitide is a peptide derived from human lactoferrin, with potential lytic and immunostimulating activities.

    • Activity

    • Anticancer

    • Target Organism

      • No MICs found on DRAMP database

    • Reference

      • Biophysical Characterization of LTX-315 Anticancer Peptide Interactions with Model Membrane Platforms: Effect of Membrane Surface Charge.(PMID: 36142470)
      • Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.(PMID: 35288467)

Clinical Information

    • Medical use

    • Solid tumors

    • Company

    • Lytix Biopharma

    • Stage of Development

    • Phase I

    • Comments

    • Upon transdermal injection directly into the tumor, ruxotemitide may bind to the tumor cell membranes and subsequently lyse tumor cells, thereby inducing tumor cell necrosis.

    • Clinical Trials

    • NCT01986426
    • NCT01058616